Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 15/20 | 0.59 |
| ▸ | KIT | P10721 | 3/20 | 0.59 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | MERTK | Q12866 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640349 | 0.88 | AXL (0.74) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL30090843 | 0.88 | AXL (0.74) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1887645 | 0.86 | AXL (0.63) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1888160 | 0.86 | AXL (0.55) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1888159 | 0.86 | AXL (0.55) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1639759 | 0.85 | AXL (0.64) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL30090790 | 0.85 | AXL (0.64) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1894493 | 0.84 | AXL (0.79) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL1640479 | 0.84 | AXL (0.71) | AXLKITFLT3AURKAEGFR | |
| SCHEMBL30090824 | 0.84 | AXL (0.81) | AXLKITFLT3AURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205592-B1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | claimed |
| US-7935693-B2 | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | claimed |
| US-20090111816-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | US | claimed |
| US-8809364-B2 | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2205592-B1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20110183986-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7935693-B2 | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090111816-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111816-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 312/4885FLT3 5/4885 |
| US-20110183986-A1 | POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KIT 312/4885FLT3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.